Sharon Tetlow

Ms. Sharon E.
Tetlow is an Independent Director at Structure Therapeutics, Inc. and a Managing Partner at Portrero Hill Advisors LLC.
She is on the Board of Directors at Structure Therapeutics, Inc., Cessation Therapeutics, Inc., DICE Molecules SV, Inc. and Shanghai ShouTi Biotechnology Co. Ltd. Ms. Tetlow was previously employed as an Independent Director by Altamont Pharma Acquisition Corp., an Independent Director by DICE Therapeutics, Inc., an Independent Member-Supervisory Board by Valneva SE, an Independent Director by Gyre Therapeutics, Inc., a Chief Financial Officer by OCERA Therapeutics LLC, a Managing Director by Danforth Advisors LLC, a Chief Financial Officer by Pathwork Diagnostics, Inc., a CFO, Secretary & SVP-Human Resources by Cell Genesys, Inc., a Venture Partner by Apax Partners, Inc., a Chief Financial Officer by diaDexus, Inc. /Old/, a Chief Financial Officer by Reprogenesis, Inc., a Chief Financial Officer by Reprogen, Inc., a Chief Financial Officer by Telik, Inc., and an Associate by The Brookings Institution.
She also served on the board at Armetheon, Inc. She received her undergraduate degree from the University of Delaware and an MBA from Stanford University.